Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before
02:42pm, Tuesday, 09'th Jun 2026
At the American Diabetes Association's 2026 Scientific Sessions, CNBC's Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss the launch of the Wegovy pill and how it became the bes
Gen Z and GLP-1 drugs to power Gym Group's growth, says analyst
11:42am, Tuesday, 09'th Jun 2026
The Gym Group PLC (LSE:GYM) remains one of Deutsche Bank's preferred stocks in the leisure sector, with the broker arguing that powerful demographic and health trends continue to support long-term gro
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.
09:25am, Tuesday, 09'th Jun 2026
Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ Kelowna, British Columbia - June 9 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NA
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
09:25am, Tuesday, 09'th Jun 2026
Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lex
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
09:20am, Tuesday, 09'th Jun 2026
More employers and health plans are balking at paying for costly GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and the treatment of obesity, according to a new report.
Promino Launches Muscle Health Research Initiative Targeting GLP-1 Weight Management Market
06:00am, Tuesday, 09'th Jun 2026
Study designed to evaluate Rejuvenate Muscle Health(TM) among GLP-1 users while generating proprietary human evidence supporting Promino's muscle health platform Burlington, Ontario--(Newsfile Corp. -
Use of GLP-1 drugs early in pregnancy should not cause alarm
05:05pm, Monday, 08'th Jun 2026
Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is not a cause for alarm, a large new data analysis suggests.
In ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C and 73.6% greater relative weight loss compared to oral semaglutide 14 mg In ACHIEVE-2 and ACHIEVE-5, Foundayo deliver
Top Stocks With Solid Shareholder Yield Amid Rising AI Valuation Concern
12:52pm, Monday, 08'th Jun 2026
As AI valuation concerns rise, CAPL, GLP, HRB and BGS stand out for strong shareholder yield and capital returns.
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
10:30am, Monday, 08'th Jun 2026
Novo Nordisk and Eli Lilly are introducing GLP-1 pills for obesity, and that competition was on display this weekend at the American Diabetes Association (ADA) Scientific Sessions. CNBC spoke to Novo
The Wegovy pill is still dominating the GLP-1 pill market
07:35pm, Sunday, 07'th Jun 2026
It has remained a top choice among Americans trying to lose weight even after the launch of Foundayo, Eli Lilly's GLP-1 pill.
In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%) In ATTAIN-2, women taking Foundayo lost significant weight
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.
02:53pm, Saturday, 06'th Jun 2026
There is a new wave of weight-loss therapies in development that aim to be better than the existing GLP-1s.
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
07:32pm, Friday, 05'th Jun 2026
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and ove
